Alnylam Achieves GAAP Profitability, Targets $5 Billion in 2026 Product Sales Fueled by Amvuttra Launch (ALNY Q4 2025 Earnings Call)
Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
Alnylam Pharmaceuticals (ALNY) delivered a watershed fourth-quarter earnings report, officially declaring its transition to sustainable GAAP profitability for the full year 2025. This long-awaited milestone validates the company's pioneering RNAi therapeutics platform and was propelled by the spectacular launch of Amvuttra for ATTR cardiomyopathy. Driven by the TTR franchise, Alnylam generated nearly $3 billion in combined net product revenues in 2025, an 81% surge compared to the prior year. Emboldened by its fortified financial position, management laid out an ambitious "Alnylam 2030" strategy, targeting a 25% revenue CAGR over the next five years and projecting combined net product sales to leap to between $4.9 billion and $5.3 billion in 2026.
Amvuttra Launch Drives Record TTR Franchise Growth
The primary engine behind Alnylam's financial inflection point is the blistering success of its TTR franchise, specifically the launch of Amvuttra for ATTR cardiomyopathy. In Q4 alone, global TTR net revenues reached $858 million, representing a staggering 151% year-over-year increase. In the U.S., where the cardiomyopathy indication launched in Q2 of 2025, revenues grew 222% year-over-year.
Management highlighted that Amvuttra is rapidly capturing market share, approaching parity with Pfizer's tafamidis in terms of new patient starts just two quarters post-launch. Crucially, the company has secured exceptional market access, with over 90% of payers providing first-line coverage—largely without step-through requirements—and the vast majority of patients incurring zero out-of-pocket costs. Looking to 2026, Alnylam expects its TTR franchise to generate between $4.4 billion and $4.7 billion, representing 83% growth at the midpoint, even while modeling for a gradual mid-single-digit net price decrease as the cardiomyopathy business scales.
Rare Disease Portfolio and Profitability Milestone
While Amvuttra dominates the narrative, Alnylam's rare disease business continues to provide a durable foundation. The franchise, anchored by GIVLAARI and OXLUMO, generated $136 million in Q4 (up 26% year-over-year) and officially crossed the $500 million mark for the full year.
This broad-based execution across the commercial portfolio allowed Alnylam to deliver $850 million in non-GAAP operating income for 2025—an incredible $755 million increase compared to 2024. Most importantly, the company achieved both GAAP and non-GAAP net income profitability for the fourth quarter and the full year, delivering on its long-stated "Alnylam P5x25" goals and ending the year with $2.9 billion in cash and marketable securities.
Alnylam 2030: The Nuceresiran Opportunity and Pipeline Expansion
With 2025's goals achieved, CEO Yvonne Greenstreet introduced the "Alnylam 2030" strategic vision. The company intends to maintain its leadership in the TTR market by advancing its next-generation therapeutic, nuceresiran. Currently in Phase 3 trials, nuceresiran offers the potential for a best-in-class profile with twice-a-year dosing. Alnylam is targeting a 2028 launch for polyneuropathy and a 2030 launch for cardiomyopathy. Notably, because Alnylam owes no royalty obligations on nuceresiran (unlike Amvuttra, which carries royalties payable to Sanofi), the transition to this new drug could dramatically expand operating margins into the mid-40s post-2030.
Beyond the TTR franchise, Alnylam is heavily reinvesting its profits into its high-yielding organic product engine. The company plans to dedicate approximately 30% of its revenues to non-GAAP R&D over the next five years. With over 25 programs currently in clinical development, Alnylam aims to launch two or more transformative medicines with blockbuster potential outside of TTR by 2030, targeting vast new indications such as hypertension (zalesiran), Alzheimer's disease, and obesity/metabolic disorders.